However, the success of most targeted therapies is predicated upon the patient's tumor exhibiting a specific targetable genomic lesion, for example V600E B-Raf in melanoma, or ERBB2 (HER2) gene amplification in breast cancer, both of which lead to increased downstream signaling and tumorigenic activity. This evidence concerns the gene ERBB2 and breast cancer.